15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Cullinan Oncology LLC, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $30.00 to $42.00, a moderate spread. The average target of $34.80 sits 60% above the current $21.72. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.73 next quarter toward $-2.71 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Cullinan Oncology LLC.
As of Sep, 5 of 5 firms rate CGEM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CGEM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.73
Range $-1.25 – $0.71 · 9 analysts · -5% YoY
Next period, 9 analysts expect Cullinan Oncology LLC to earn $-0.73 a share (range $-1.25 – $0.71), versus $-0.77 a year earlier. Full-year consensus is $-3.17, growing to $-2.71 the year after.
REVENUE · NEXT QUARTER
$11.6M
Range $0 – $104.0M · 9 analysts
Revenue is expected to reach $11.6M (range $0 – $104.0M). Full-year consensus is $13.9M, rising to $38.2M next year.
Top analysts covering Cullinan Oncology LLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CGEM.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #3
Buy
$28.00+28.9% to target
Overall win rate
64%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #121
Buy
No targeton CGEM
Overall win rate
56%
+ Follow
#3
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Buy
$30.00+38.1% to target
Overall win rate
41%
+ Follow
#4
EW
Edward White
HC Wainwright & Co. · Rank #290
Buy
$33.00+51.9% to target
Overall win rate
31%
+ Follow
#5
Robert Driscoll
Wedbush · Rank #375
Buy
$42.00+93.4% to target
Overall win rate
30%
+ Follow
CGEM stock forecast FAQ
What is CGEM's average 12-month price target?+
The 5 analysts with a live target average $34.80 for Cullinan Oncology LLC over the next 12 months, ranging from a $42.00 high to a $30.00 low.
Is CGEM stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CGEM?+
The Street-high target is $42.00 (Wedbush), and the Street-low is $30.00 (HC Wainwright & Co.). The average of all 5 active targets is $34.80.
How many Wall Street analysts cover CGEM?+
5 analysts have an active rating on Cullinan Oncology LLC, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering CGEM?+
Among analysts who currently cover CGEM, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #3). Their current call is Buy with a $28.00 target.
What is Cullinan Oncology LLC's projected EPS for next quarter?+
The consensus estimate is $-0.73 per share (range $-1.25 – $0.71) across 9 analysts. Full-year EPS is projected at $-3.17, rising to $-2.71 the following year.
How much revenue is Cullinan Oncology LLC expected to report next quarter?+
Consensus revenue is $11.6M (range $0 – $104.0M). Full-year revenue is projected at $13.9M, growing to $38.2M next year.
Have analysts been upgrading or downgrading CGEM lately?+
As of Sep, 5 of 5 firms rate CGEM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CGEM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
